Positional Adaptability in the Design of Mutation-Resistant Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors: A Supramolecular Perspective

被引:0
作者
Bruccoleri, Aldo [1 ]
机构
[1] Canadian Univ Coll, Fac Sci Chem, Lacombe, AB T4L 2E5, Canada
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; RNASE-H ACTIVITY; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; WILD-TYPE; HYDROQUINONE; FLUORESCENCE; FLEXIBILITY; NUCLEOSIDE; MECHANISM;
D O I
10.1089/aid.2012.0141
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Drug resistance is a key cause of failed treatment of HIV infection. The efficacy of nonnucleoside reverse transcriptase-inhibiting (NNRTI) drugs is impaired by the rapid emergence of drug-resistant mutations. The literature supports the idea that purposefully designed flexible NNRTIs at an active site may help overcome drug resistance. It is proposed here that the usual "lock and key" model, with respect to NNRTI drug design, be expanded to consider creating "master keys" that would automatically adjust conformations to fit all of the "locks" mutations may make. The present work introduces the novel perspective of designing and creating supramolecular assemblies as potential NNRTIs (instead of the relatively more rigid single-molecule inhibitors). Specifically, flexible self-assembling quinhydrone supramolecular dimers formed from quinonoid monomers (designed to be highly flexible NNRTIs themselves) will be offered as a working example of this new perspective in NNRTI drug design. Quinonoid compounds have demonstrated binding interactions at various sites of the HIV-1 RT enzyme, including the elusive ribonuclease H area. Quinhydrone self-organized dimers have at some point in their molecular architecture a noncovalently interacting donor-acceptor ring pair complex. This complex is at the heart of the increased torsional, rotational, and translational motion this species will experience at a particular active site. Flexible supramolecular assemblies, together with their flexible monomer components, may offer a critical advantage in retaining potency against a wide range of drug-resistant HIV-1 RTs. This new supramolecular perspective may also have broader implications in the general field of antimicrobial drug design.
引用
收藏
页码:4 / 12
页数:9
相关论文
共 50 条
[21]   Considerations for Structure-Based Drug Design Targeting HIV-1 Reverse Transcriptase [J].
Arnold, Eddy ;
Martinez, Sergio E. ;
Bauman, Joseph D. ;
Das, Kalyan .
MULTIFACETED ROLES OF CRYSTALLOGRAPHY IN MODERN DRUG DISCOVERY, 2015, :69-81
[22]   Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors [J].
Chen, Xiaomei ;
Ding, Li ;
Tao, Yuan ;
Pannecouque, Christophe ;
De Clercq, Erik ;
Zhuang, Chunlin ;
Chen, Fen-Er .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 202
[23]   Structure of HIV-1 nonnucleoside reverse transcriptase inhibitors derivatives of N-benzyl-benzimidazole with different substituents in position 4 [J].
Ziolkowska, Natasza E. ;
Michejda, Christopher J. ;
Bujacz, Grzegorz D. .
JOURNAL OF MOLECULAR STRUCTURE, 2010, 963 (2-3) :188-193
[24]   NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities [J].
Thammaporn, Ratsupa ;
Yagi-Utsumi, Maho ;
Yamaguchi, Takumi ;
Boonsri, Pornthip ;
Saparpakorn, Patchreenart ;
Choowongkomon, Kiattawee ;
Techasakul, Supanna ;
Kato, Koichi ;
Hannongbua, Supa .
SCIENTIFIC REPORTS, 2015, 5
[25]   In Vitro Selection of HIV-1 CRF08_BC Variants Resistant to Reverse Transcriptase Inhibitors [J].
Wu, Hao ;
Zhang, Xiao-Min ;
Zhang, Hao-Jie ;
Zhang, Qiwei ;
Chen, Zhiwei ;
Huang, Jian-Dong ;
Lee, Shui-Shan ;
Zheng, Bo-Jian .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2015, 31 (02) :260-270
[26]   Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors [J].
Famiglini, Valeria ;
Coluccia, Antonio ;
Brancale, Andrea ;
Pelliccia, Sveva ;
La Regina, Giuseppe ;
Silvestri, Romano .
FUTURE MEDICINAL CHEMISTRY, 2013, 5 (18) :2141-2156
[27]   In Vitro and In Vivo Activities of AIC292, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor [J].
Wildum, Steffen ;
Paulsen, Daniela ;
Thede, Kai ;
Ruebsamen-Schaeff, Helga ;
Zimmermann, Holger .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (11) :5320-5329
[28]   Altered Viral Fitness and Drug Susceptibility in HIV-1 Carrying Mutations That Confer Resistance to Nonnucleoside Reverse Transcriptase and Integrase Strand Transfer Inhibitors [J].
Hu, Zixin ;
Kuritzkes, Daniel R. .
JOURNAL OF VIROLOGY, 2014, 88 (16) :9268-9276
[29]   Molecular Docking Studies of HIV-1 Resistance to Reverse Transcriptase Inhibitors: Mini-Review [J].
Tarasova, Olga ;
Poroikov, Vladimir ;
Veselovsky, Alexander .
MOLECULES, 2018, 23 (05)
[30]   Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors [J].
Pribut, Nicole ;
Basson, Adriaan E. ;
van Otterlo, Willem A. L. ;
Liotta, Dennis C. ;
Pelly, Stephen C. .
ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (02) :196-202